Next Article in Journal / Special Issue
Ethical Challenges in Organoid Use
Previous Article in Journal / Special Issue
Biosafety of Genome Editing Applications in Plant Breeding: Considerations for a Focused Case-Specific Risk Assessment in the EU
 
 
Opinion

Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations

1
School of Humanities, Social Sciences and Economics, International Hellenic University, 57001 Thermi, Greece
2
Section of Ecology and Taxonomy, School of Biology, National and Kapodistrian University of Athens, Zografou Campus, 16784 Athens, Greece
3
Leiden University Medical Center, Department of Health, Safety and the Environment, Leiden University, 9500 Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Maestri Enrico
BioTech 2021, 10(3), 11; https://doi.org/10.3390/biotech10030011
Received: 23 April 2021 / Revised: 11 June 2021 / Accepted: 22 June 2021 / Published: 23 June 2021
(This article belongs to the Special Issue Biotechnology and Bioethics)
Rheumatoid Arthritis (RA) is an autoimmune and inflammatory disease that affects the synovium (lining that surrounds the joints), causing the immune system to attack its own healthy tissues. Treatment options, to the current day, have serious limitations and merely offer short-term alleviation to the pain. Using a theoretical exercise based on literature, a new potentially viable therapy has been proposed. The new therapy focusses on a long-term treatment of RA based on gene therapy, which is only active when inflammation of the joint occurs. This treatment will prevent side effects of systemic application of drugs. Furthermore, the benefits of this treatment for the patient from a socio-economic perspective has been discussed, focusing on the quality of life of the patent and lower costs for the society. View Full-Text
Keywords: rheumatoid arthritis; gene therapy; medical biosafety; environmental biosafety; adeno-associated virus; vector rheumatoid arthritis; gene therapy; medical biosafety; environmental biosafety; adeno-associated virus; vector
Show Figures

Figure 1

MDPI and ACS Style

Tsitrouli, Z.; Akritidou, M.-A.; Genitsaris, S.; Willigen, G.v. Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations. BioTech 2021, 10, 11. https://doi.org/10.3390/biotech10030011

AMA Style

Tsitrouli Z, Akritidou M-A, Genitsaris S, Willigen Gv. Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations. BioTech. 2021; 10(3):11. https://doi.org/10.3390/biotech10030011

Chicago/Turabian Style

Tsitrouli, Zinovia, Maria-Anna Akritidou, Savvas Genitsaris, and Gijsbert van Willigen. 2021. "Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations" BioTech 10, no. 3: 11. https://doi.org/10.3390/biotech10030011

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop